Literature DB >> 23415377

Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy.

Nazareno Suardi1, Andrea Gallina2, Giuliana Lista2, Giorgio Gandaglia2, Firas Abdollah2, Umberto Capitanio2, Paolo Dell'Oglio2, Alessandro Nini2, Andrea Salonia2, Francesco Montorsi2, Alberto Briganti2.   

Abstract

BACKGROUND: Little is known about the impact of adjuvant radiation therapy (aRT) after radical prostatectomy (RP) on urinary continence (UC).
OBJECTIVE: To evaluate the impact of aRT on UC recovery in patients with unfavourable pathologic characteristics. DESIGN, SETTING, AND PARTICIPANTS: The study included 361 patients with either pT2 with positive surgical margin(s) or pT3a/pT3b node-negative disease treated with RP at a tertiary care referral centre. INTERVENTION: Patients were stratified according to the administration of aRT into two groups: group 1 (no aRT; n=208; 57.8%) and group 2 (aRT; n=153; 42.2%). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Continence was defined as no use of protective pads. Log-rank test was used to compare the rate of UC recovery according to aRT status. The association between aRT and UC was also tested in Cox regression models after accounting for age, Cancer of the Prostate Risk Assessment (CAPRA) score, nerve-sparing (NS) status, Charlson Comorbidity Index, body mass index, and year of surgery. RESULTS AND LIMITATIONS: At a mean follow-up of 30 mo, 254 patients (70.4%) recovered complete UC. The 1- and 3-yr UC recovery was 51% and 59% for patients submitted to aRT versus 81% and 87% for patients not receiving aRT, respectively (p<0.001). At univariable analysis, older age (p<0.001), presence of non-organ-confined disease (p<0.001), non-NS procedure (p<0.001), and delivery of aRT (p<0.001) were significantly associated with lower UC. At multivariable analysis, the delivery of aRT remained an independent predictor of worse UC recovery (hazard ratio: 0.57; p=0.001). Patients treated with aRT had a 1.6-fold higher risk of incontinence. Younger age (p=0.02), lower CAPRA score (p=0.03), and NS approach (p<0.001) also represented independent predictors of UC recovery. The main limitations of the study are related to the lack of validated questionnaires in the evaluation of UC and in the lack of information regarding UC status at aRT.
CONCLUSIONS: The delivery of aRT has a detrimental effect on UC. The oncologic benefits must be balanced with an impaired UC recovery. Patients should be informed of such impairment before adjuvant treatments are planned.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvant radiation therapy; Prostate cancer; Radical prostatectomy; Urinary continence

Mesh:

Year:  2013        PMID: 23415377     DOI: 10.1016/j.eururo.2013.01.027

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  21 in total

1.  Contemporary Role of the Decipher® Test in Prostate Cancer Management: Current Practice and Future Perspectives.

Authors:  Deepansh Dalela; Björn Löppenberg; Akshay Sood; Jesse Sammon; Firas Abdollah
Journal:  Rev Urol       Date:  2016

2.  Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome.

Authors:  Georgios Hatzichristodoulou; Stefan Wagenpfeil; Gregor Weirich; Michael Autenrieth; Tobias Maurer; Mark Thalgott; Thomas Horn; Matthias Heck; Kathleen Herkommer; Jürgen E Gschwend; Hubert Kübler
Journal:  World J Urol       Date:  2015-06-23       Impact factor: 4.226

3.  Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy.

Authors:  Georg Müller; Malte Rieken; Gernot Bonkat; Joel Roman Gsponer; Tatjana Vlajnic; Christian Wetterauer; Thomas C Gasser; Stephen F Wyler; Alexander Bachmann; Lukas Bubendorf
Journal:  Virchows Arch       Date:  2014-08-17       Impact factor: 4.064

Review 4.  Extraprostatic extension in prostate cancer: primer for radiologists.

Authors:  Alice C Shieh; Ezgi Guler; Vijayanadh Ojili; Raj Mohan Paspulati; Robin Elliott; Nikhil H Ramaiya; Sree Harsha Tirumani
Journal:  Abdom Radiol (NY)       Date:  2020-12

5.  Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.

Authors:  G Gandaglia; G Lista; N Fossati; N Suardi; A Gallina; M Moschini; L Bianchi; M S Rossi; R Schiavina; S F Shariat; A Salonia; F Montorsi; A Briganti
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-02-09       Impact factor: 5.554

6.  Post-prostatectomy radiotherapy adversely affects urinary continence irrespective of radiotherapy regime.

Authors:  J N Nyarangi-Dix; J Steimer; T Bruckner; H Jakobi; S A Koerber; B Hadaschik; J Debus; M Hohenfellner
Journal:  World J Urol       Date:  2017-08-31       Impact factor: 4.226

7.  Patterns and timing of artificial urinary sphincter failure.

Authors:  Andrew Jason Cohen; Kristine Kuchta; Sangtae Park; Jaclyn Milose
Journal:  World J Urol       Date:  2018-01-30       Impact factor: 4.226

Review 8.  The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer.

Authors:  Giorgio Gandaglia; Cesare Cozzarini; Alexandre Mottrie; Alberto Bossi; Nicola Fossati; Francesco Montorsi; Alberto Briganti
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

9.  Appraisal of the role of radical prostatectomy for rhabdomyosarcoma in children: oncological and urological outcome.

Authors:  Lorenzo Angelini; Gianni Bisogno; Ciro Esposito; Marco Castagnetti
Journal:  Ther Adv Urol       Date:  2018-03-07

10.  Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China.

Authors:  Dingwei Ye; Wei Zhang; Lulin Ma; Chuanjun Du; Liping Xie; Yiran Huang; Qiang Wei; Zhangqun Ye; Yanqun Na
Journal:  Chin J Cancer Res       Date:  2019-06       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.